$GRTSQ
Gritstone bio, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022007902 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $7.191M $39.69M
YoY Change -81.88% 3045.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.955M $6.940M
YoY Change 14.63% 26.87%
% of Gross Profit
Research & Development $28.20M $24.86M
YoY Change 13.45% 10.63%
% of Gross Profit
Depreciation & Amortization $1.589M $1.600M
YoY Change -0.69% -1.84%
% of Gross Profit
Operating Expenses $36.15M $31.80M
YoY Change 13.7% 13.83%
Operating Profit -$28.96M $7.896M
YoY Change -466.81% -129.61%
Interest Expense $47.00K $27.00K
YoY Change 74.07% -94.19%
% of Operating Profit 0.34%
Other Income/Expense, Net
YoY Change
Pretax Income -$28.92M $7.920M
YoY Change -465.1% -130.22%
Income Tax
% Of Pretax Income
Net Earnings -$28.92M $7.923M
YoY Change -464.96% -130.23%
Net Earnings / Revenue -402.11% 19.96%
Basic Earnings Per Share -$0.34 $0.10
Diluted Earnings Per Share -$0.34 $0.10
COMMON SHARES
Basic Shares Outstanding 86.28M 75.99M
Diluted Shares Outstanding 86.28M 77.46M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $172.2M $198.0M
YoY Change -13.05% 81.82%
Cash & Equivalents $69.16M $108.5M
Short-Term Investments $103.0M $89.50M
Other Short-Term Assets $990.0K $513.0K
YoY Change 92.98% 39.78%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $224.0K
Total Short-Term Assets $192.5M $202.5M
YoY Change -4.94% 80.32%
LONG-TERM ASSETS
Property, Plant & Equipment $22.28M $21.69M
YoY Change 2.72% -54.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $6.854M $2.700M
YoY Change 153.85% 0.0%
Total Long-Term Assets $50.97M $44.40M
YoY Change 14.8% -12.43%
TOTAL ASSETS
Total Short-Term Assets $192.5M $202.5M
Total Long-Term Assets $50.97M $44.40M
Total Assets $243.5M $246.9M
YoY Change -1.39% 51.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.641M $6.400M
YoY Change -11.86% 28.0%
Accrued Expenses $1.350M $12.00M
YoY Change -88.75% 34.83%
Deferred Revenue $12.32M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.09M $21.80M
YoY Change 56.36% 18.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.19M $25.80M
YoY Change -21.73% -11.64%
Total Long-Term Liabilities $20.19M $25.80M
YoY Change -21.73% -11.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.09M $21.80M
Total Long-Term Liabilities $20.19M $25.80M
Total Liabilities $54.28M $47.60M
YoY Change 14.04% -0.06%
SHAREHOLDERS EQUITY
Retained Earnings -$430.3M -$318.4M
YoY Change 35.14% 28.81%
Common Stock $20.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $189.2M $199.4M
YoY Change
Total Liabilities & Shareholders Equity $243.5M $246.9M
YoY Change -1.39% 51.46%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$28.92M $7.923M
YoY Change -464.96% -130.23%
Depreciation, Depletion And Amortization $1.589M $1.600M
YoY Change -0.69% -1.84%
Cash From Operating Activities -$33.50M $10.70M
YoY Change -413.08% -146.57%
INVESTING ACTIVITIES
Capital Expenditures $1.812M $990.0K
YoY Change 83.03% -38.47%
Acquisitions
YoY Change
Other Investing Activities $9.446M -$88.61M
YoY Change -110.66% -640.96%
Cash From Investing Activities $7.634M -$89.60M
YoY Change -108.52% -706.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.103M
YoY Change -62.84%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -917.0K 17.40M
YoY Change -105.27% 207.6%
NET CHANGE
Cash From Operating Activities -33.50M 10.70M
Cash From Investing Activities 7.634M -89.60M
Cash From Financing Activities -917.0K 17.40M
Net Change In Cash -26.73M -61.55M
YoY Change -56.57% 2315.66%
FREE CASH FLOW
Cash From Operating Activities -$33.50M $10.70M
Capital Expenditures $1.812M $990.0K
Free Cash Flow -$35.31M $9.710M
YoY Change -463.67% -139.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001656634
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38663
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Gritstone bio, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4859534
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5959 Horton Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
CY2022Q1 dei City Area Code
CityAreaCode
510
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
871-6100
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
GRTS
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72812833
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69158000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93287000
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
103004000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
108346000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
9395000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
11285000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10946000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7672000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
192503000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
220590000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5290000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6005000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22283000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21622000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21832000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22920000
CY2022Q1 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
1564000
CY2021Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2352000
CY2022Q1 grts Long Term Marketable Securities
LongTermMarketableSecurities
0
CY2021Q4 grts Long Term Marketable Securities
LongTermMarketableSecurities
4617000
CY2022Q1 us-gaap Assets
Assets
243472000
CY2021Q4 us-gaap Assets
Assets
278106000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5641000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4230000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4285000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6925000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1350000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
411000
CY2022Q1 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3601000
CY2021Q4 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3706000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6886000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7483000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12324000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17201000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
34087000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39956000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18689000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18936000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1505000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3128000
CY2022Q1 us-gaap Liabilities
Liabilities
54281000
CY2021Q4 us-gaap Liabilities
Liabilities
62020000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72779508
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72779508
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69047878
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69047878
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
20000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
619862000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
617523000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-391000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-73000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-430300000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401384000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
189191000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
216086000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
243472000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278106000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7191000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39693000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28199000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24856000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7955000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6941000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
36154000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
31797000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28963000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
7896000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
47000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
27000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28916000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7923000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-318000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-3000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29234000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7920000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86277599
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75987372
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86277599
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77464356
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
216086000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-318000
CY2022Q1 grts Tax Payments Related To Shares Withheld For Vested Restricted Stock Units
TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits
-890000
CY2022Q1 grts Issuance Of Common Stock For Warrant Exercises Value
IssuanceOfCommonStockForWarrantExercisesValue
34000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3131000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28916000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
189191000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
166739000
CY2021Q1 grts Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants
AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants
-451000
CY2021Q1 grts Stock Issued During Period Value Purchase Agreement
StockIssuedDuringPeriodValuePurchaseAgreement
20839000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-3000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
279000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1824000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2201000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7923000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
199351000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28916000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7923000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1589000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1595000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-196000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-107000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3131000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2201000
CY2022Q1 grts Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
2332000
CY2021Q1 grts Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
1900000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3273000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
182000
CY2022Q1 grts Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
-787000
CY2021Q1 grts Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
7000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1861000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1637000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2640000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2510000
CY2022Q1 grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
121000
CY2021Q1 grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
-51000
CY2022Q1 grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-105000
CY2021Q1 grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
505000
CY2022Q1 grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-2034000
CY2021Q1 grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-1950000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6500000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-514000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33451000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10654000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28342000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
89610000
CY2022Q1 grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
26573000
CY2021Q1 grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
1000000
CY2022Q1 grts Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
11215000
CY2021Q1 grts Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1812000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
990000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7634000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-89600000
CY2022Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
69000
CY2021Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5878000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-917000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17395000
CY2022Q1 grts Payments Of Financing Lease
PaymentsOfFinancingLease
-56000
CY2021Q1 grts Payments Of Financing Lease
PaymentsOfFinancingLease
0
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
890000
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
0
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26734000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-61551000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110577000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171048000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83843000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109497000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1182000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
509000
CY2022Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2021Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
46000
CY2022Q1 grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
228000
CY2021Q1 grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
0
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28900000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7900000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33500000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10700000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-430300000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401400000
CY2022Q1 grts Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
172200000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the condensed consolidated balance sheets. As of March 31, 2022, the Company has no off-balance sheet concentrations of credit risk.</span></p>
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69158000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93287000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
9395000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
11285000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5290000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6005000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
83843000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110577000
CY2020Q2 grts Use Of Net Operating Losses Suspension Period For Medium And Large Business
UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness
P3Y
CY2020Q2 grts Use Of Business Incentive Tax Credits Period Cap
UseOfBusinessIncentiveTaxCreditsPeriodCap
P3Y
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
157087000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
194348000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
73000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
157478000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
391000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
194275000
CY2022Q1 grts Marketable Securities Realized Gain Loss Description
MarketableSecuritiesRealizedGainLossDescription
no material realized gains or losses
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2022Q1 grts Period Of Unrealized Loss Position
PeriodOfUnrealizedLossPosition
12 months or greater
CY2022Q1 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
42295000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
41907000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23837000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22276000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22283000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21622000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6144000
CY2022Q1 grts Operating Lease Payment Under The Boston Lease
OperatingLeasePaymentUnderTheBostonLease
79114000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2253000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1900000
CY2022Q1 us-gaap Lease Cost
LeaseCost
2253000
CY2021Q1 us-gaap Lease Cost
LeaseCost
1900000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2034000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1950000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
781000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5M9D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6M3D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7621000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6837000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12527000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10658000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
10376000
CY2022Q1 grts Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
62814000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
110833000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
25575000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6886000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18689000
CY2022Q1 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
5728000
CY2021Q4 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
2672000
CY2021Q4 grts Facilities Related Deposits
FacilitiesRelatedDeposits
0
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
990000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
866000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10946000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7672000
CY2022Q1 grts Net Contract Asset
NetContractAsset
0
CY2021Q4 grts Net Contract Asset
NetContractAsset
1385000
CY2022Q1 grts Collaboration Receivable
CollaborationReceivable
2235000
CY2021Q4 grts Collaboration Receivable
CollaborationReceivable
688000
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1314000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1769000
CY2022Q1 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
224000
CY2021Q4 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
292000
CY2022Q1 grts Facilities Related Deposits
FacilitiesRelatedDeposits
455000
CY2022Q1 us-gaap Security Deposit
SecurityDeposit
934000
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
1305000
CY2022Q1 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
630000
CY2021Q4 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
1047000
CY2022Q1 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
1564000
CY2021Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2352000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1169591
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72779508
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69047878
CY2022Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s common stock are entitled to one vote per share.
CY2019Q4 grts Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
250000000.0
CY2019Q4 grts Maximum Offering Expenses Agreed To Be Reimbursed
MaximumOfferingExpensesAgreedToBeReimbursed
50000
CY2021 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3990869
CY2022Q1 grts Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
250000000.0
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4000000.0
CY2022Q1 grts Class Of Warrant Or Right Issue Date
ClassOfWarrantOrRightIssueDate
2020-12-28
CY2022Q1 grts Class Of Warrant Or Rights Expiration
ClassOfWarrantOrRightsExpiration
None
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13573704
CY2022Q1 grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
3442567
CY2021Q1 grts Warrants Issued
WarrantsIssued
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3459187
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5107335
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.82
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M17D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17153000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2761915
CY2022Q1 grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted
2550341
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2200168
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.61
CY2022Q1 grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised
0
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73713
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.87
CY2022Q1 grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled
338523
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
302640
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.21
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4009284
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6931150
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.56
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M10D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1016000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2329666
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.94
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
996000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6076920
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.65
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1013000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3900000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
22300000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
708800
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.29
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
350173
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.46
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
353300
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
5.29
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
35883
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
5.31
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
669790
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.38
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3131000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2201000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28916000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7923000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86277599
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75987372
CY2022Q1 grts Effect Of Dilutive Shares
EffectOfDilutiveShares
0
CY2021Q1 grts Effect Of Dilutive Shares
EffectOfDilutiveShares
1476984
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86277599
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77464356
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7708450
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1417134

Files In Submission

Name View Source Status
0000950170-22-007902-index-headers.html Edgar Link pending
0000950170-22-007902-index.html Edgar Link pending
0000950170-22-007902.txt Edgar Link pending
0000950170-22-007902-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grts-20220331.htm Edgar Link pending
grts-20220331.xsd Edgar Link pending
grts-20220331_cal.xml Edgar Link unprocessable
grts-20220331_def.xml Edgar Link unprocessable
grts-20220331_htm.xml Edgar Link completed
grts-20220331_lab.xml Edgar Link unprocessable
grts-20220331_pre.xml Edgar Link unprocessable
grts-ex31_1.htm Edgar Link pending
grts-ex31_2.htm Edgar Link pending
grts-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending